MCF Advisors LLC Sells 49 Shares of Becton, Dickinson and Company (NYSE:BDX)

MCF Advisors LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 23.1% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 163 shares of the medical instruments supplier’s stock after selling 49 shares during the quarter. MCF Advisors LLC’s holdings in Becton, Dickinson and Company were worth $40,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. O Shaughnessy Asset Management LLC boosted its stake in Becton, Dickinson and Company by 53.0% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 10,566 shares of the medical instruments supplier’s stock valued at $2,732,000 after purchasing an additional 3,661 shares during the last quarter. Synovus Financial Corp lifted its holdings in shares of Becton, Dickinson and Company by 70.4% during the third quarter. Synovus Financial Corp now owns 7,196 shares of the medical instruments supplier’s stock valued at $1,861,000 after purchasing an additional 2,972 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Becton, Dickinson and Company by 116.3% during the third quarter. Tower Research Capital LLC TRC now owns 10,194 shares of the medical instruments supplier’s stock valued at $2,635,000 after buying an additional 5,482 shares during the last quarter. Bank of Nova Scotia increased its holdings in Becton, Dickinson and Company by 40.6% in the 3rd quarter. Bank of Nova Scotia now owns 54,217 shares of the medical instruments supplier’s stock worth $14,016,000 after buying an additional 15,662 shares in the last quarter. Finally, Nomura Holdings Inc. raised its position in Becton, Dickinson and Company by 5.7% in the 3rd quarter. Nomura Holdings Inc. now owns 4,418 shares of the medical instruments supplier’s stock worth $1,142,000 after buying an additional 238 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the transaction, the senior vice president now owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $236.70, for a total value of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares in the company, valued at $3,457,713.60. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock valued at $2,033,381 in the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.2 %

BDX opened at $233.71 on Friday. The firm’s 50 day simple moving average is $234.36 and its two-hundred day simple moving average is $237.85. The company has a market capitalization of $67.54 billion, a PE ratio of 51.48, a PEG ratio of 2.02 and a beta of 0.44. Becton, Dickinson and Company has a 1-year low of $224.00 and a 1-year high of $287.32. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the prior year, the business posted $2.86 EPS. Becton, Dickinson and Company’s revenue was up 4.6% on a year-over-year basis. As a group, equities analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. The ex-dividend date was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Ratings Changes

BDX has been the topic of a number of recent analyst reports. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price target on the stock. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Barclays increased their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a report on Monday, May 6th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.17.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.